We've detected an Ad Blocker in your browser.
Please disable or pause the Ad Blocker and refresh the page to be able to register and access the website normally.
A KDIGO and TMA initiative in partnership with Radcliffe Cardiology
MTE & Satellite Symposium Sessions
(Please note this programme is subject to change)
Day 1 – Friday, 24 March
- 16:10-16:50 ICT | 10:10-10:50 CET | 06:10-06:50 BRT
Satellite symposiumSGLT2 inhibitors in cardio-renal-metabolic patients – the perfect fit?
Chair – Michel Jadoul, BE
- SGLT2 inhibitors – the perfect fit for cardio-metabolic patients? – Paola Fioretto, IT
- SGLT2 inhibitors – the perfect fit for cardio-renal patients? – Stefan Anker, DE
- SGLT2 inhibitors – the perfect fit for renal-metabolic patients? – Michel Jadoul, BE
- Panel discussion
- 20:20-20:50 ICT | 14:20-14:50 CET | 10:20-10:50 BRT
Meet the expertManagement of heart failure in real world clinical practice – insights from the REWOLUTION HF surveys
Ewa Jankowska, PL and Andrew Coats, AU
- 22:10-22:40 ICT | 16:10-16:40 CET | 12:10-12:40 BRT
Meet the expertImplementation patterns and challenges in HF care: insights from the EVOLUTION HF study
Orly Vardeny, US and Gianluigi Savarese, SE
Supported by an educational grant from AstraZeneca. - 02:10-02:50 ICT | 20:10-20:50 CET | 16:10-16:50 BRT
Meet the expertSingle pill combination (SPC) in Cardiorenal metabolic (CRM) disease
Stefan Anker, DE and Muthiah Vaduganathan, US
Day 2 – Saturday, 25 March
- 16:10-16:50 ICT | 10:10-10:50 CET | 06:10-06:50 BRT
Satellite symposiumManagement of CKD without diabetes – SGLT2 inhibitors, the new standard of care
Chair – Michel Jadoul, BE
- Burden of CKD without diabetes – Michel Jadoul, BE
- Role of SGLT2 inhibitors in non-diabetic CKD – supporting evidence – David Wheeler, UK
- SGLT2 inhibitors – a new standard of care for CKD without diabetes – Pinar Topsever, TR
- Panel discussion
- 20:20-20:50 ICT | 14:20-14:50 CET | 10:20-10:50 BRT
Meet the expertManagement of hyperkalemia in cardiorenal disease ‒ practical guidance and novel therapeutic options
Gianluigi Savarese, SE and Jolanta Małyszko, PL
Supported by an unrestricted educational grant by CSL Vifor. - 22:10-22:50 ICT | 16:10-16:50 CET | 12:10-12:50 BRT
Satellite symposium
Management of hyperkalemia across the cardiorenal spectrum
Chair – Matthew R Weir, US
- The challenge of hyperkalemia in cardiorenal disease – Andrew Coats, AU
- Best practice recommendations for hyperkalemia management: across the cardiorenal spectrum – Shelley Zieroth, CA
- Enabling guideline-recommended RAASi therapy to protect the heart and the kidneys – Kieran McCafferty, UK
- Panel discussion
- 02:10-02:50 ICT | 20:10-20:50 CET | 16:10-16:50 BRT
Meet the expertManagement of heart failure in real world clinical practice – insights from the REWOLUTION HF surveys
Ewa Jankowska, PL and Andrew Coats, AU
If you’re interested in becoming an educational partner or sponsor at this event, please contact sales@radcliffe-group.com
About KDIGO
KDIGO is a global organisation developing and implementing evidence-based clinical practice guidelines in kidney disease. It is an independent, volunteer-led, self-managed foundation incorporated in Belgium and accountable to the public and the patients it serves.
KDIGO’s mission is to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines.
For more information on KDIGO, please visit https://kdigo.org.
About Translational Medicine Academy
Our ambition at the Translational Medicine Academy® (TMA) is to bring medical findings from bench to bedside and into the working lives of physicians and the care of patients. In seeking to improve therapeutic approaches, TMA works with its International Scientific Advisory Board on Critical Mission Areas® of public health importance in domains where there are educational shortcomings among physicians and unmet healthcare needs among patients.
Gathered around a Scientific Advisory Board of experts, the Translational Medicine Academy is an international non-profit Foundation with headquarter in Basel, and offices in Paris, and the US. TMA’s funding includes private donations from individuals and educational grants from governments, non-governmental organizations and corporations.
For more information on TMA, please visit www.tmacademy.org.
About Radcliffe Cardiology
We are Radcliffe, a knowledge network for the cardiovascular community.
We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.
We bring medical knowledge to life
From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.
Our work is underpinned by 3 core principles:
- We build on the best science
- We work hands-on with our community
- We bring fresh thinking
Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.
For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com.
Please contact events@radcliffe-group.com should you have any queries.